

THE DEVASTATING IMPACT OF

CARDIAC AMYLOIDOSIS



CARDIAC AMYLOIDOSIS is caused by **MISFOLDED PROTEINS** that build up in the heart and other parts of the body.¹

ATTR-CM (transthyretin amyloid cardiomyopathy) and **AL** (Immunoglobulin light chain amyloidosis) account for the majority of cardiac amyloidosis cases.²

ATTR-CM is:



LIFE-Threatening^{3,4}



UNDERDIAGNOSED^{3,4}



Associated with **HEART FAILURE**^{3,4}

SYMPTOMS of HEART FAILURE:



SHORTNESS of BREATH^{4,5}



SWELLING⁶

PATIENT PERSPECTIVES FROM A US SURVEY⁷

DIAGNOSIS

for cardiac amyloidosis patients is often a **LONG AND COMPLEX JOURNEY**



Almost

70%

of patients **SAID THEIR CONCERNS** about cardiac amyloidosis symptoms were **IGNORED BY OTHER HCPs** prior to diagnosis⁷



MORE THAN HALF

reported being **MISDIAGNOSED** with another condition prior to diagnosis⁷

On average, patients reported seeing

4-5



DOCTORS for symptoms related to cardiac amyloidosis prior to a diagnosis⁷

The **PHYSICAL AND SOCIAL IMPACT**

on cardiac amyloidosis patients is **SIGNIFICANT**

76%

of patients agreed that due to their cardiac amyloidosis they often had to **PUT THEIR LIFE ON PAUSE** (eg, by avoiding things like):



TRAVELLING



SWITCHING JOBS



SOCIALISING



PHYSICAL FITNESS

More than **70%**

of patients said cardiac amyloidosis negatively impacts their **ROMANTIC RELATIONSHIPS/INTIMACY** a lot or a great deal⁷



Nearly **70%**



of patients living with cardiac amyloidosis said they generally **NEVER FEEL WELL**⁷

The **EMOTIONAL TOLL**

of cardiac amyloidosis on patients **CANNOT BE OVERLOOKED**

FRUSTRATED
STRESSED
OVERWHELMED

Common words patients used to **DESCRIBE THEIR FEELINGS** toward living with cardiac amyloidosis⁷

81%



of patients reported that **NO ONE UNDERSTANDS** the **NEGATIVE IMPACT** cardiac amyloidosis has on their everyday life⁷

2/3



of patients were either **VERY** or **EXTREMELY CONCERNED** about their current health⁷



Visit yourheartmessage.ie and speak to your doctor for more information about ATTR-CM

1. Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. *Cleveland Clinic Journal of Medicine*. 2017;84(12 suppl 3):12-26. doi:10.3949/ccjm.84.s3.02.
2. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. *Circulation*. 2016;133(24):2404-2412. doi:10.1161/circulationaha.116.021612.
3. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification. *Amyloid*. 2016;23(4): 209-213.
4. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. *Circulation*. 2017;135(14):1357-1377.
5. Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy. *Current Opinion in Cardiology*. 2018;1. doi:10.1097/hco.0000000000000547.
6. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. *Circulation*. 2012;126(10):1286-1300.
7. Pfizer Data on File. Survey Conducted by Harris Poll, 2018.